What is it about?
Steroid-resistant asthma is one of the phenotypes of patients with severe asthma. However, how the enhancement of type 2 inflammation alters steroid sensitivity in asthma is not clear. Thus, in this study, we aimed to clarify the association of suppressing type 2 inflammation by benralizumab (anti-IL-5 receptor antibody) with the expression levels of key molecules involved in steroid response in patients with severe asthma.
Featured Image
Photo by freestocks on Unsplash
Why is it important?
Our results suggested that benralizumab treatment restored the expression levels of key molecules involved in steroid response through PI3K pathway inactivation. We believe that our study makes a significant contribution to the literature because it identifies a potential mechanism underlying steroid resistance by type 2 inflammation.
Perspectives
We believe that this paper will provide a better understanding of the pathophysiology of severe asthma with type 2 inflammation, and we hope that it will help improve the management of asthma patients.
Keita Hirai
University of Shizuoka
Read the Original
This page is a summary of: Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma, Allergy, March 2021, Wiley,
DOI: 10.1111/all.14819.
You can read the full text:
Resources
Contributors
The following have contributed to this page
